BioCentury
ARTICLE | Company News

AgonOx, Daiichi Sankyo deal

October 10, 2016 7:00 AM UTC

The companies partnered for the preclinical development of an undisclosed AgonOx immuno-oncology target. After a preclinical assessment, Daiichi may exercise an exclusive option for worldwide rights t...